<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-164305</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Coats&#146; disease with macular oedema responsive to aflibercept and argon laser</dc:title>
<dc:description xml:lang="en">Clinical case: A 14 year-old boy with Coats&#146; disease in his right eye, presented with a visual acuity (VA) of 0.1, micro-aneurysms, exudates, a macular oedema of 959 microns, and peripheral telangiectasias. After 12 months follow-up with 6 ranibizumab injections and 3 sessions of argon laser photocoagulation, the macular oedema remained and VA was 0.2. Following 4 aflibercept injections and another 2 laser sessions, he had a good foveal slope and a VA of 0.5, with no recurrences in the last 12 months. Discussion: Treatment with aflibercept and argon laser was effective in our patient with stage 2B Coats&#146; disease and macular oedema unresponsive to ranibizumab (AU)</dc:description>
<dc:creator>Pardo Saiz, AO</dc:creator>
<dc:creator>Guixeres Esteve, MC</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Caso clínico: Varón de 14 años con enfermedad de Coats en su ojo derecho. Agudeza visual (AV) 0,1. Microaneurismas, exudados, edema macular de 959&amp;#956;m y telangiectasias periféricas. Tras 12 meses iniciales con 6 inyecciones de ranibizumab y 3 sesiones de láser argón, persistía edema macular de 553&amp;#956;m y AV 0,2. Después de 4 dosis de aflibercept y otras 2 sesiones de láser, presenta buen perfil foveal y AV 0,5, sin recurrencias desde hace 12 meses. Discusión: El tratamiento con aflibercept combinado con láser argón, resultó efectivo en nuestro paciente con enfermedad de Coats en estadio 2B y edema macular, con respuesta incompleta al ranibizumab (AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;92(7): 330-333, jul. 2017. ilus</dc:source>
<dc:identifier>ibc-164305</dc:identifier>
<dc:title xml:lang="es">Enfermedad de Coats con edema macular sensible al aflibercept y láser argón</dc:title>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d52875^s22073</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d53977^s22057</dc:subject>
<dc:subject>^d28131^s22057</dc:subject>
<dc:subject>^d55979^s22073</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d34460^s22079</dc:subject>
<dc:subject>^d24817^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201707</dc:date>
</metadata>
</record>
</ibecs-document>
